Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. [electronic resource]
Producer: 20130524Description: 1221-32 p. digitalISSN:- 1573-2592
- Acitretin -- pharmacology
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal -- pharmacology
- CD8-Positive T-Lymphocytes -- drug effects
- Dermatitis, Atopic -- blood
- Down-Regulation -- drug effects
- Drug Administration Schedule
- Etanercept
- Female
- Humans
- Immunoglobulin G -- pharmacology
- Interleukin-10 -- genetics
- Interleukin-17 -- genetics
- Keratolytic Agents -- pharmacology
- Lymphocyte Count
- Male
- Middle Aged
- Psoriasis -- blood
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Signal Transduction -- drug effects
- Skin -- drug effects
- Th1 Cells -- drug effects
- Th17 Cells -- drug effects
- Th2 Cells -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.